(BDX) Becton Dickinson - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 40.678m USD | Total Return: 10.2% in 12m
Avg Turnover: 502M
EPS Trend: 87.0%
Qual. Beats: -2
Rev. Trend: 96.8%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Confidence
Becton, Dickinson and Company (BDX) is a global medical technology company that develops and manufactures a broad range of medical supplies, laboratory equipment, and diagnostic products. The company operates through specialized segments including Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. Its portfolio spans from high-volume consumables like syringes and catheters to complex systems for medication management, genomics, and surgical intervention.
The company operates within the Health Care Equipment sub-industry, a sector characterized by high research and development costs and rigorous regulatory oversight. BDX utilizes a diversified business model that balances recurring revenue from disposable medical supplies with long-term capital placements in pharmacy automation and diagnostic laboratory systems. This integration into hospital workflows often creates high switching costs for healthcare providers.
Investors can further evaluate these operational segments and historical performance trends by reviewing the detailed analytics on ValueRay.
- Alaris infusion pump remediation and regulatory clearance drive core medical segment recovery
- Expansion of high-margin prefillable syringe capacity supports long-term biopharma systems growth
- Hospital capital expenditure cycles influence demand for automated medication dispensing systems
- Strategic acquisitions in the interventional segment diversify revenue beyond traditional medical supplies
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.43 > 1.0 |
| NWC/Revenue: -2.32% < 20% (prev 4.67%; Δ -6.99% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.90b > Net Income 1.14b |
| Net Debt (16.5b) to EBITDA (4.65b): 3.54 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (280.6m) vs 12m ago -2.96% < -2% |
| Gross Margin: 46.48% > 18% (prev 0.45%; Δ 4.60k% > 0.5%) |
| Asset Turnover: 40.58% > 50% (prev 38.31%; Δ 2.27% > 0%) |
| Interest Coverage Ratio: 4.03 > 6 (EBITDA TTM 4.65b / Interest Expense TTM 563.0m) |
| A: -0.01 (Total Current Assets 8.01b - Total Current Liabilities 8.51b) / Total Assets 50.8b |
| B: 0.34 (Retained Earnings 17.4b / Total Assets 50.8b) |
| C: 0.04 (EBIT TTM 2.27b / Avg Total Assets 52.6b) |
| D: 0.60 (Book Value of Equity 16.0b / Total Liabilities 26.7b) |
| Altman-Z'' = 1.97 = BBB |
| DSRI: 0.71 (Receivables 2.21b/3.03b, Revenue 21.4b/20.9b) |
| GMI: 0.96 (GM 46.48% / 44.50%) |
| AQI: 1.01 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 1.02 (Revenue 21.4b / 20.9b) |
| TATA: -0.05 (NI 1.14b - CFO 3.90b) / TA 50.8b) |
| Beneish M = -3.34 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 147.75 with a total of 3,243,481 shares traded.
Over the past week, the price has changed by +3.79%,
over one month by -1.64%,
over three months by -15.83% and
over the past year by +10.23%.
Becton Dickinson has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BDX.
- StrongBuy: 6
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 183.3 | 24.1% |
P/E Trailing = 25.7644
P/E Forward = 11.7647
P/S = 1.8301
P/B = 1.6856
P/EG = 1.1074
Revenue TTM = 21.4b USD
EBIT TTM = 2.27b USD
EBITDA TTM = 4.65b USD
Long Term Debt = 14.7b USD (from longTermDebt, last quarter)
Short Term Debt = 2.57b USD (from shortTermDebt, last quarter)
Debt = 17.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.5b USD (calculated: Debt 17.3b - CCE 816.0m)
Enterprise Value = 57.1b USD (40.7b + Debt 17.3b - CCE 816.0m)
Interest Coverage Ratio = 4.03 (Ebit TTM 2.27b / Interest Expense TTM 563.0m)
EV/FCF = 18.19x (Enterprise Value 57.1b / FCF TTM 3.14b)
FCF Yield = 5.50% (FCF TTM 3.14b / Enterprise Value 57.1b)
FCF Margin = 14.71% (FCF TTM 3.14b / Revenue TTM 21.4b)
Net Margin = 5.33% (Net Income TTM 1.14b / Revenue TTM 21.4b)
Gross Margin = 46.48% ((Revenue TTM 21.4b - Cost of Revenue TTM 11.4b) / Revenue TTM)
Gross Margin QoQ = 45.69% (prev 44.63%)
Tobins Q-Ratio = 1.12 (Enterprise Value 57.1b / Total Assets 50.8b)
Interest Expense / Debt = 3.26% (Interest Expense 563.0m / Debt 17.3b)
Taxrate = 10.84% (204.0m / 1.88b)
NOPAT = 2.02b (EBIT 2.27b * (1 - 10.84%))
Current Ratio = 0.94 (Total Current Assets 8.01b / Total Current Liabilities 8.51b)
Debt / Equity = 0.72 (Debt 17.3b / totalStockholderEquity, last quarter 24.1b)
Debt / EBITDA = 3.54 (Net Debt 16.5b / EBITDA 4.65b)
Debt / FCF = 5.24 (Net Debt 16.5b / FCF TTM 3.14b)
Total Stockholder Equity = 25.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.16% (Net Income 1.14b / Total Assets 50.8b)
RoE = 4.54% (Net Income TTM 1.14b / Total Stockholder Equity 25.1b)
RoCE = 5.70% (EBIT 2.27b / Capital Employed (Equity 25.1b + L.T.Debt 14.7b))
RoIC = 4.50% (NOPAT 2.02b / Invested Capital 44.9b)
WACC = 6.16% (E(40.7b)/V(58.0b) * Re(7.54%) + D(17.3b)/V(58.0b) * Rd(3.26%) * (1-Tc(0.11)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -1.66%
[DCF] Terminal Value 77.97% ; FCFF base≈2.92b ; Y1≈3.35b ; Y5≈4.93b
[DCF] Fair Price = 209.4 (EV 74.2b - Net Debt 16.5b = Equity 57.7b / Shares 275.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.00 | EPS CAGR: 7.68% | SUE: -1.90 | # QB: -2
Revenue Correlation: 96.77 | Revenue CAGR: 5.39% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.13 | Chg30d=+1.39% | Revisions=+60% | Analysts=12
EPS current Year (2026-09-30): EPS=12.55 | Chg30d=+0.66% | Revisions=+69% | GrowthEPS=-12.8% | GrowthRev=-12.1%
EPS next Year (2027-09-30): EPS=13.45 | Chg30d=-0.44% | Revisions=+33% | GrowthEPS=+7.1% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: +69%